Edition:
India

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

35.37USD
17 Nov 2017
Change (% chg)

$-0.19 (-0.53%)
Prev Close
$35.56
Open
$35.33
Day's High
$35.49
Day's Low
$35.17
Volume
5,980,857
Avg. Vol
4,868,122
52-wk High
$36.78
52-wk Low
$30.51

Select another date:

Fri, Nov 17 2017

Photo

FDA expands approval for Pfizer cancer drug Sutent

The U.S. Food and Drug Administration on Thursday approved the use of Pfizer Inc's cancer drug Sutent to help prevent kidney cancer from returning following surgical removal of a kidney.

U.S. FDA expands approval for Pfizer cancer drug Sutent

Nov 16 The U.S. Food and Drug Administration on Thursday approved the use of Pfizer Inc's cancer drug Sutent to help prevent kidney cancer from returning following surgical removal of a kidney.

Pfizer, Novartis agree UK price cuts for new breast cancer drugs

LONDON Pfizer and Novartis have agreed price cuts for their rival breast cancer drugs Ibrance and Kisqali to ensure they can be used routinely within Britain's state-funded health service.

Pfizer, Novartis agree UK price cuts for new breast cancer drugs

LONDON, Nov 16 Pfizer and Novartis have agreed price cuts for their rival breast cancer drugs Ibrance and Kisqali to ensure they can be used routinely within Britain's state-funded health service.

UPDATE 1-Pfizer creates chief operating officer role for Bourla

NEW YORK, Nov 13 Drugmaker Pfizer Inc has promoted Albert Bourla to the newly created post of chief operating officer, freeing up Chief Executive Officer Ian Read to focus more on long-term strategy and engaging with government and industry leaders.

BRIEF-Pfizer names Albert Bourla chief operating officer

* Pfizer - ‍albert Bourla has been group president of co's innovative health business since beginning of 2016​

Pfizer exits China joint venture for generic drugs

Nov 10 Pfizer Inc said on Friday it has sold its 49 percent stake to exit a joint venture it had set up with China's Zhejiang Hisun Pharmaceuticals in 2012 to develop and market generic drugs.

UPDATE 1-Novartis takes fight to Pfizer's Ibrance with new Kisqali data

* Class of CDK4/6 cancer drugs getting crowded (Adds details, company and analyst comment)

BRIEF-Spark Therapeutics and Pfizer amend license agreement for investigational SPK-9001 in hemophilia B

* Spark Therapeutics and Pfizer amend license agreement for investigational SPK-9001 in hemophilia B

Pfizer expects broad interest for consumer health business

NEW YORK Pfizer Inc, the largest U.S. drugmaker, expects no shortage of suitors for its consumer health business and said it would decide whether to sell, spin off or retain the unit next year. | Video

Select another date: